Catumaxomab, Representing a New Generation of Antibodies, Proved Efficient and Safe in Malignant Ascites / Data presented at 44th annual ASCO congress, Chicago, USA
München, Deutschland und Chicago, USA (ots) - Treatment with the trifunctional antibody catumaxomab significantly prolongs puncture-free survival in patients with malignant ascites, according to the results from a Phase II/III trial presented at the 44th American Society of Clinical Oncology (ASCO) congress. ...
mehr